THE RITZ-CARLTON LEADERSHIP CENTER UNWRAPS SUMMIT 2025, AN EXPLORATION OF DYNAMIC NEW CONTENT TO REKINDLE ORGANIZATIONAL CULTURE FOR SUCCESS IN TODAY’S WORKPLACE 
Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference
BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company...
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated...
Modular Medical Proudly Sponsors the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an...
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of...
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group
HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of...
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder...
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a...
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer...
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present...
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunitiesSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024...
ALIGNMT AI and HFMA Collaborate to Offer AI Governance Micro-Credentialing for Healthcare Professionals
Empowering Healthcare Professionals with Advanced AI Governance Skills to Drive Responsible Innovation NEW YORK, Nov. 11, 2024 /PRNewswire/ -- ALIGNMT AI,...
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11,...
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe...
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical...
CBD of Denver Announces Q3 Revenue and Updates on Spinoff and German Market
Q3 Financial PerformanceDenver, Colorado--(Newsfile Corp. - November 10, 2024) - CBD of Denver (OTC Pink: CBDD) is pleased to report...
KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment
RIYADH, Saudi Arabia, Nov. 10, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) announced a significant...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS...